FLT3 and acute myeloid leukemia: In addition, in this cohort the majority of FLT3-ITD + AML patients (54%) harbored more than one ITD of different leukemic subclones which is related to the higher sensitivity of NGS compared to conventional DNA fragment analyses [25]; 84% of these patients exhibited one dominant FLT3-ITD clone with an NGS-cAR at least twice as high as the sum of the NGS-cARs of the co-occurring ITDs.